Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
We send one confirmation email first. Only emails about VERA, unsubscribe in one click. Privacy
Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.
| Drug | Indication | Most advanced trial | Status |
|---|---|---|---|
| Atacicept FDA approved Jul 2026 · Trutakna |
IgA Nephropathy | Phase 3 · NCT04716231 | Active not recruiting |
| MAU868 | BK Virus Infection | Phase 2 · NCT04294472 | Completed |
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
VERA holds $499.2M in cash and short-term investments (as of Jun 30, 2026) and burns about $103.4M/quarter from operations, an estimated runway of 14.5 months at that rate (BioRadar estimate, not company guidance).
Dilution pressure: 50 · Elevated
Recent financing filings on SEC EDGAR:
Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when VERA files for a raise →
| Holder | Type | Shares | % of shares | As of |
|---|---|---|---|---|
| Avoro Capital Advisors LLC | Institution (13F) | 5,723,888 | 7.94% | 2026-06-30 |
| BlackRock, Inc. | Institution (13G, 5%+) | 5,340,522 | 7.41% | 2026-06-30 |
| T. Rowe Price Associates, Inc. | Institution (13G, 5%+) | 4,573,684 | 6.35% | 2026-03-31 |
| STATE STREET CORPORATION | Institution (13G, 5%+) | 4,148,786 | 5.76% | 2026-06-30 |
| Deep Track Capital, LP | Institution (13G, 5%+) | 3,921,362 | 5.44% | 2026-03-04 |
| Deerfield Management Company, L.P | Institution (13F) | 3,916,400 | 5.43% | 2026-06-30 |
| Kynam Capital Management, LP | Institution (13F) | 2,890,059 | 4.01% | 2026-06-30 |
| Morgan Stanley | Institution (13F) | 2,799,459 | 3.88% | 2026-06-30 |
| Sofinnova Investments, Inc. | Institution (13F) | 2,793,987 | 3.88% | 2026-06-30 |
| FMR, LLC | Institution (13F) | 2,774,070 | 3.85% | 2026-06-30 |
| Marshall Fordyce PRESIDENT AND CEO, Director · +626,301 options |
Insider | 235,244 | 0.33% | 2026-09-15 |
| Sean Grant CHIEF FINANCIAL OFFICER · +50,000 options |
Insider | 119,181 | 0.17% | 2026-02-23 |
Share count 72,063,335 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest (13F quarter ending 2026-06-30). Sources have different dates, so the split is approximate. Source: SEC EDGAR.
| Trade date | Insider | Transaction | Shares | Price | Owned after |
|---|---|---|---|---|---|
| 2026-09-15 filed 2026-09-17 |
Fordyce Marshall |
Sale (S) | 18,500 | $37.00 | 235,244 |
| 2026-09-15 filed 2026-09-17 |
Fordyce Marshall |
Option exercise (M) | 18,500 | – | – |
| 2026-09-15 filed 2026-09-17 |
Fordyce Marshall |
Option exercise (M) | 18,500 | $2.90 | 253,744 |
| 2026-09-11 filed 2026-09-14 |
Young Joseph R |
Option exercise (M) | 5,000 | – | – |
| 2026-09-11 filed 2026-09-14 |
Young Joseph R |
Option exercise (M) | 5,000 | $3.94 | 80,754 |
Only open-market purchases (P) and sales (S) are trading decisions. Awards (A), option exercises (M) and tax withholding (F) are compensation mechanics. Source: SEC Form 4.
| Date | Drug | Type | Run-up 30d | Decision 1d | After 5d |
|---|---|---|---|---|---|
| 2026-07-07 | TRUTAKNA | BLA | +28.3% | +7.1% | — |
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for VERA and every other ticker you follow. Card required, cancel anytime.
Start 7-day free trial →